Has an Angel Shown the Way? Etiological and Therapeutic Implications of the PCP/NMDA Model of Schizophrenia
Open accessThe DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Abstract
Over the last 20 years, glutamatergic models of schizophrenia have become increasingly accepted as etiopathological models of schizophrenia, based on the observation that phencyclidine (PCP) induces a schizophrenia-like psychosis by blocking neurotransmission at N-methyl-D-aspartate (NMDA)-type glutamate receptors. This article reviews developments in two key predictions of the model: first, that neurocognitive deficits in schizophrenia should follow the pattern of deficit predicted based on underlying NMDAR dysfunction and, second, that agents that stimulate NMDAR function should be therapeutically beneficial. As opposed to dopamine receptors, NMDAR are widely distributed throughout the brain, including subcortical as well as cortical brain regions, and sensory as well as association cortex. Studies over the past 20 years have documented severe sensory dysfunction in schizophrenia using behavioral, neurophysiological, and functional brain imaging approaches, including impaired generation of key sensory-related potentials such as mismatch negativity and visual P1 potentials. Similar deficits are observed in humans following administration of NMDAR antagonists such as ketamine in either humans or animal models. Sensory dysfunction, in turn, predicts impairments in higher order cognitive functions such as auditory or visual emotion recognition. Treatment studies have been performed with compounds acting directly at the NMDAR glycine site, such as glycine, D-serine, or D-cycloserine, and, more recently, with high-affinity glycine transport inhibitors such as RG1678 (Roche). More limited studies have been performed with compounds targeting the redox site. Overall, these compounds have been found to induce significant beneficial effects on persistent symptoms, suggesting novel approaches for treatment and prevention of schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glycine potentiates the NMDA response in cultured mouse brain neurons
Johnson, J. W., & Ascher, P. (1987) · Nature · doi:10.1038/325529a0 · Cited by 3,139
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Self-citationThe Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
Howes, O. D., & Kapur, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp006 · Cited by 2,693
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685
Allen, N. C., Bagade, S., McQueen, M. B., Ioannidis, J. P. A., Kavvoura, F. K., Khoury, M. J., Tanzi, R. E., & Bertram, L. (2008) · Nature Genetics · doi:10.1038/ng.171 · Cited by 1,054
Schell, M. J., Molliver, M. E., & Snyder, S. H. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.3948 · Cited by 832
Elevated Striatal Dopamine Function Linked to Prodromal Signs of Schizophrenia
Howes, O. D., Montgomery, A. J., Asselin, M.-C., Murray, R. M., Valli, I., Tabraham, P., Bramon-Bosch, E., Valmaggia, L., Johns, L., Broome, M., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.514 · Cited by 744
Javitt, D. C., Steinschneider, M., Schroeder, C. E., & Arezzo, J. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11962 · Cited by 662
Self-citationThe Glutamatergic Dysfunction Hypothesis for Schizophrenia
Coyle, J. T. (1996) · Harvard Review of Psychiatry · doi:10.3109/10673229609017192 · Cited by 568
Increased Synaptic Dopamine Function in Associative Regions of the Striatum in Schizophrenia
Kegeles, L. S., Abi-Dargham, A., Frankle, W. G., Gil, R., Cooper, T. B., Slifstein, M., Hwang, D.-R., Huang, Y., Haber, S. N., & Laruelle, M. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.10 · Cited by 565
Altered neuregulin 1–erbB4 signaling contributes to NMDA> receptor hypofunction in schizophrenia
Hahn, C.-G., Wang, H.-Y., Cho, D.-S., Talbot, K., Gur, R. E., Berrettini, W. H., Bakshi, K., Kamins, J., Borgmann-Winter, K. E., Siegel, S. J., et al. (2006) · Nature Medicine · doi:10.1038/nm1418 · Cited by 563
Berk, M., Copolov, D., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., Judd, F., Katz, F., Katz, P., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.03.004 · Cited by 552
When Doors of Perception Close: Bottom-up Models of Disrupted Cognition in Schizophrenia
Javitt, D. C. (2009) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.032408.153502 · Cited by 503
Self-citationEfficacy of High-Dose Glycine in the Treatment of Enduring Negative Symptoms of Schizophrenia
Heresco-Levy, U., Javitt, D. C., Ermilov, M., Mordel, C., Silipo, G., & Lichtenstein, M. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.1.29 · Cited by 487
Self-citationKantrowitz, J. T., & Javitt, D. C. (2010) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2010.04.006 · Cited by 396
Self-citationHeresco-Levy, U., Javitt, D. C., Ebstein, R., Vass, A., Lichtenberg, P., Bar, G., Catinari, S., & Ermilov, M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.12.037 · Cited by 386
Self-citationGlutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients
Lavoie, S., Murray, M. M., Deppen, P., Knyazeva, M. G., Berk, M., Boulat, O., Bovet, P., Bush, A. I., Conus, P., Copolov, D., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301624 · Cited by 371
Early-stage visual processing and cortical amplification deficits in schizophrenia
Butler, P. D., Zemon, V., Schechter, I., Saperstein, A. M., Hoptman, M. J., Lim, K. O., Revheim, N., Silipo, G., & Javitt, D. C. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.5.495 · Cited by 362
Self-citationSensory Processing in Schizophrenia: Neither Simple nor Intact
Javitt, D. C. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp110 · Cited by 327
Self-citationPrediction of Psychosis by Mismatch Negativity
Bodatsch, M., Ruhrmann, S., Wagner, M., Müller, R., Schultze-Lutter, F., Frommann, I., Brinkmeyer, J., Gaebel, W., Maier, W., Klosterkötter, J., et al. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.09.057 · Cited by 283
Hong, L. E., Summerfelt, A., Buchanan, R. W., O'Donnell, P., Thaker, G. K., Weiler, M. A., & Lahti, A. C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.168 · Cited by 274
Tsai, G., & Lin, P.-Y. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790361452 · Cited by 269
Umbricht, D., Koller, R., Vollenweider, F. X., & Schmid, L. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01242-2 · Cited by 258
Self-citationHigh dose D-serine in the treatment of schizophrenia
Kantrowitz, J. T., Malhotra, A. K., Cornblatt, B., Silipo, G., Balla, A., Suckow, R. F., D'Souza, C., Saksa, J., Woods, S. W., & Javitt, D. C. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.012 · Cited by 253
Self-citationAnti-NMDA-receptor encephalitis: A severe, multistage, treatable disorder presenting with psychosis
Wandinger, K.-P., Saschenbrecker, S., Stoecker, W., & Dalmau, J. (2011) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.09.012 · Cited by 243
Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia.
Javitt, D. (1987) · PubMed · Cited by 240
Self-citationHigh-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia
Heresco-Levy, U., Ermilov, M., Lichtenberg, P., Bar, G., & Javitt, D. C. (2004) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00707-8 · Cited by 222
Self-citationGlutamatergic drugs for schizophrenia: a systematic review and meta-analysis
Tuominen, H. J., Tiihonen, J., & Wahlbeck, K. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2004.05.005 · Cited by 209
Meta-Analysis of the Efficacy of Adjunctive NMDA Receptor Modulators in Chronic Schizophrenia
Singh, S. P., & Singh, V. (2011) · CNS Drugs · doi:10.2165/11586650-000000000-00000 · Cited by 194
Cortical Kynurenine Pathway Metabolism: A Novel Target for Cognitive Enhancement in Schizophrenia
Wonodi, I., & Schwarcz, R. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq002 · Cited by 190
Umbricht, D., Vollenweider, F. X., Schmid, L., Grübel, C., Skrabo, A., Huber, T., & Koller, R. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300005 · Cited by 187
Self-citationPharmacodynamics of Memantine: An Update
Parsons, C., Rammes, G., & Danysz, W. (2008) · Current Neuropharmacology · doi:10.2174/157015908783769671 · Cited by 183
Translating Glutamate: From Pathophysiology to Treatment
Javitt, D. C., Schoepp, D., Kalivas, P. W., Volkow, N. D., Zarate, C., Merchant, K., Bear, M. F., Umbricht, D., Hajos, M., Potter, W. Z., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002804 · Cited by 168
Self-citationPowell, S. B., Sejnowski, T. J., & Behrens, M. M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.049 · Cited by 164
Sarcosine (N-Methylglycine) Treatment for Acute Schizophrenia: A Randomized, Double-Blind Study
Lane, H.-Y., Liu, Y.-C., Huang, C.-L., Chang, Y.-C., Liau, C.-H., Perng, C.-H., & Tsai, G. E. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.04.038 · Cited by 164
Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis
Heekeren, K., Daumann, J., Neukirch, A., Stock, C., Kawohl, W., Norra, C., Waberski, T. D., & Gouzoulis-Mayfrank, E. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1129-4 · Cited by 152
Neurodevelopment, neuroplasticity, and new genes for schizophrenia
Arnold, S. E., Talbot, K., & Hahn, C.-G. (2004) · Progress in brain research · doi:10.1016/s0079-6123(04)47023-x · Cited by 152
Sensory Contributions to Impaired Emotion Processing in Schizophrenia
Butler, P. D., Abeles, I. Y., Weiskopf, N. G., Tambini, A., Jalbrzikowski, M., Legatt, M. E., Zemon, V., Loughead, J., Gur, R. C., & Javitt, D. C. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp109 · Cited by 147
Self-citationThe Neural Substrates of Impaired Prosodic Detection in Schizophrenia and Its Sensorial Antecedents
Leitman, D. I., Hoptman, M. J., Foxe, J. J., Saccente, E., Wylie, G. R., Nierenberg, J., Jalbrzikowski, M., Lim, K. O., & Javitt, D. C. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.3.474 · Cited by 146
Self-citationEarly Sensory Contributions to Contextual Encoding Deficits in Schizophrenia
Dias, E. C., Butler, P. D., Hoptman, M. J., & Javitt, D. C. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.17 · Cited by 139
Self-citationPinard, E., Alanine, A., Alberati, D., Bender, M., Borroni, E., Bourdeaux, P., Brom, V., Burner, S., Fischer, H., Hainzl, D., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100210p · Cited by 135
Sehatpour, P., Dias, E. C., Butler, P. D., Revheim, N., Guilfoyle, D. N., Foxe, J. J., & Javitt, D. C. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.85 · Cited by 134
Self-citationHashimoto, K., Fujita, Y., Horio, M., Kunitachi, S., Iyo, M., Ferraris, D. V., & Tsukamoto, T. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.002 · Cited by 128
Karlsgodt, K. H., Robleto, K., Trantham-Davidson, H., Jairl, C., Cannon, T. D., Lavin, A., & Jentsch, J. D. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.09.012 · Cited by 119
Norton, D. J., McBain, R. K., Holt, D. J., Öngür, D., & Chen, Y. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.026 · Cited by 110
Javitt, D. C., Balla, A., Burch, S., Suckow, R. F., Xie, S., & Sershen, H. W. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300313 · Cited by 108
Self-citationReversal of phencyclidine-induced effects by glycine and glycine transport inhibitors
Javitt, D. C., Balla, A., Sershen, H. W., & Lajtha, Á. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00237-6 · Cited by 107
Self-citationCortical glutamate–dopamine interaction and ketamine-induced psychotic symptoms in man
Aalto, S., Ihalainen, J. A., Hirvonen, J., Kajander, J., Scheinin, H., Tanila, H., Någren, K., Vilkman, H., Gustafsson, L. L., Syvälahti, E. K. G., et al. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0092-6 · Cited by 107
Schobel, S. A., Kelly, M. A., Corcoran, C. M., Van Heertum, K., Seckinger, R., Goetz, R., Harkavy-Friedman, J., & Malaspina, D. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.07.016 · Cited by 102
Roffman, J. L., Weiss, A. P., Purcell, S., Caffalette, C. A., Freudenreich, O., Henderson, D. C., Bottiglieri, T., Wong, D. H., Halsted, C. H., & GOFF, D. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.12.017 · Cited by 97
Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification.
Javitt, D. C. (2009) · PubMed · Cited by 96
Self-citationConsequences of Magnocellular Dysfunction on Processing Attended Information in Schizophrenia
Martinez, A., Hillyard, S. A., Bickel, S., Dias, E. C., Butler, P. D., & Javitt, D. C. (2012) · Cerebral Cortex · doi:10.1093/cercor/bhr195 · Cited by 94
Self-citationEffects of NMDA receptor antagonist memantine on mismatch negativity
Korostenskaja, M., Nikulin, V. V., Kičić, D., Nikulina, A. V., & Kähkönen, S. (2007) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2007.01.007 · Cited by 91
Ketamine effects on brain function — Simultaneous fMRI/EEG during a visual oddball task
Musso, F., Brinkmeyer, J., Ecker, D., London, M. K., Thieme, G., Warbrick, T., Wittsack, H., Saleh, A., Greb, W., de Boer, P., et al. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.06.045 · Cited by 91
Kulak, A., Cuenod, M., & Do, K. Q. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.10.020 · Cited by 90
Li, D., & He, L. (2007) · Genetics in Medicine · doi:10.1097/01.gim.0000250507.96760.4b · Cited by 79
Dose-related effects of memantine on a mismatch negativity-like response in anesthetized rats
Tikhonravov, D. L., Neuvonen, T., Pertovaara, A., Savioja, K., Ruusuvirta, T., Näätänen, R., & Carlson, S. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.03.014 · Cited by 78
Balla, A., Sershen, H. W., Serra, M., Koneru, R., & Javitt, D. C. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300019 · Cited by 77
Self-citationJavitt, D. C., Sershen, H., Hashim, A., & Lajtha, A. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00047-x · Cited by 74
Self-citationKantrowitz, J. T., Leitman, D. I., Lehrfeld, J. M., Laukka, P., Juslin, P. N., Butler, P. D., Silipo, G., & Javitt, D. C. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr060 · Cited by 71
Self-citationG72/G30 Genes and Schizophrenia: A Systematic Meta-analysis of Association Studies
Li, D., & He, L. (2007) · Genetics · doi:10.1534/genetics.106.061796 · Cited by 67
Neurophysiological and neurochemical animal models of schizophrenia: Focus on glutamate☆
Bickel, S., & Javitt, D. C. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.05.005 · Cited by 66
Self-citationAmelioration of ketamine-induced working memory deficits by dopamine D1 receptor agonists
Roberts, B. M., Seymour, P. A., Schmidt, C. J., Williams, G. V., & Castner, S. A. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1840-9 · Cited by 61
Hashimoto, K., Nishiyama, S., Ohba, H., Matsuo, M., Kobashi, T., Takahagi, M., Iyo, M., Kitashoji, T., & Tsukada, H. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003231 · Cited by 58
D-serine adjuvant treatment alleviates behavioural and motor symptoms in Parkinson's disease
Gelfin, E., Kaufman, Y., Korn‐Lubetzki, I., Bloch, B., Kremer, I., Javitt, D. C., & Heresco‐Levy, U. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001015 · Cited by 58
Self-citationBalla, A., Nattini, M. E., Sershen, H., Lajtha, A., Dunlop, D. S., & Javitt, D. C. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.01.021 · Cited by 55
Self-citationShinkai, T., Luca, V. D., Hwang, R., Müller, D. J., Lanktree, M. B., Zai, G. C., Shaikh, S. A., Wong, G. W. H., Sicard, T., Potapova, N., et al. (2007) · NeuroMolecular Medicine · doi:10.1007/bf02685890 · Cited by 54
Glycine transporter inhibition reverses ketamine-induced working memory deficits
Roberts, B. M., Shaffer, C. L., Seymour, P. A., Schmidt, C. J., Williams, G. V., & Castner, S. A. (2010) · NeuroReport · doi:10.1097/wnr.0b013e3283381a4e · Cited by 50
The Neural Substrates of Impaired Prosodic Detection in Schizophrenia and Its Sensorial Antecedents
Leitman, D. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.164.3.474 · Cited by 45
A novel alanine-insensitive d-serine transporter in rat brain synaptosomal membranes
Javitt, D. C., Balla, A., & Sershen, H. W. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02557-x · Cited by 31
Self-citationWylie, G. R., Clark, E. A., Butler, P. D., & Javitt, D. C. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn119 · Cited by 30
Self-citationSershen, H. W., Balla, A., Aspromonte, J., Xie, S., Cooper, T. B., & Javitt, D. C. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.07.011 · Cited by 28
Self-citationLinn, G. S., O’Keeffe, R. T., Lifshitz, K., Schroeder, C. E., & Javitt, D. C. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0771-6 · Cited by 28
Self-citationInhibition of striatal dopamine release by glycine and glycyldodecylamide
Javitt, D. C., Sershen, H. W., Hashim, A., & Lajtha, Á. (2000) · Brain Research Bulletin · doi:10.1016/s0361-9230(00)00258-6 · Cited by 27
Self-citationSlifstein, M., Suckow, R. F., Javitch, J. A., Cooper, T. B., Lieberman, J. A., & Abi‐Dargham, A. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.91 · Cited by 22
Kantrowitz, J. T., Oakman, E., Bickel, S., Citrome, L., Spielman, A., Silipo, G., Battaglia, J., & Javitt, D. C. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.03.035 · Cited by 21
Self-citationBalla, A., Schneider, S., Sershen, H. W., & Javitt, D. C. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.03.006 · Cited by 18
Self-citationBarbero (2014) · doi:10.1016/j · Cited by 1
Research works printed but not linked: 4
- 6. Roberts BM, Seymour PA, Schmidt CJ, Williams GV, Castner SA. Amelioration of ketamine-induced working memory deficits by dopamine D1 receptor agonists. Psychopharmacology (Berl) . 2010;210:407-418.
- 2011, Science Translational Medicine, 3, 102mr102
- 64. Umbricht D, Yoo K, Youssef E, et al. Glycine transporter type 1 (GL YT1) inhibitor RG1678: positive results of the proof-of-concept study for the treatment of negative symptoms in schizophrenia. Neuropsychopharmacol. 2010;35:s320-321.
- 2010, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 35, s320
Cited by
Jauhar, S., Johnstone, M., & McKenna, P. J. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01730-x · Cited by 996
Kaar, S. J., Natesan, S., McCutcheon, R., & Howes, O. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107704 · Cited by 383
Hashimoto, K. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12902 · Cited by 335
Reviewing the ketamine model for schizophrenia
Frohlich, J., & Van Horn, J. D. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113512909 · Cited by 303
“Finally, prefrontal hypodopaminergia models predict that during task-switching paradigms, schizophrenia patients should have increased switch cost (poorer performance immediately following switching) (Javitt et al., 2012).”
BackgroundInfluentialKindler, J., Lim, C. K., Weickert, C. S., Boerrigter, D., Galletly, C., Liu, D., Jacobs, K. R., Balzan, R., Bruggemann, J., O’Donnell, M., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0401-9 · Cited by 284
Metadata
- Authors
- Javitt, D. C., Zukin, S. R., Heresco-Levy, U., & Umbricht, D.
- Affiliations
- Nathan Kline Institute for Psychiatric Research (US)
- Johns Hopkins University (US)
- F. Hoffmann-La Roche AG (CH)
- Corresponding author
- Javitt, D. C.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-09-01
- Volume
- 38
- Issue
- 5
- Pages
- 958-966
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- PMC
- PMC3446214
- OpenAlex
- W2165209294
- Cited by
- 322
- References
- 76
- Citations by year
- 2026: 2 · 2025: 13 · 2024: 15 · 2023: 11 · 2022: 20 · 2021: 21 · 2020: 26 · 2019: 40 · 2018: 20 · 2017: 22 · 2016: 27 · 2015: 38 · 2014: 36 · 2013: 29 · 2012: 2
- FWCI
- 4.53
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Schizophrenia Bulletin (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health (R37MH049334, R37MH49334, P50MH086385, R01MH049334)
- National Institute on Drug Abuse (R01DA03383, R01DA003383)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- schizophrenia, NMDA receptor hypofunction
- MeSH terms
- Animals, Brain, Brain Mapping, Cerebral Cortex, Cognition Disorders, Contingent Negative Variation, Disease Models, Animal, Drug Synergism, Glycine, Hippocampus, Humans, Ketamine, Synaptic Transmission, Perception, Phencyclidine, Psychoses, Substance-Induced, Schizophrenia, Antipsychotic Agents, Receptors, N-Methyl-D-Aspartate, Receptors, Dopamine D2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.